Regenxbio, Duchenne muscular dystrophy and gene therapy
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne, commemorated its 30th ...
Capricor Therapeutics (NASDAQ:CAPR) announced Wednesday that the European Medicines Agency has issued Orphan Drug and ...
Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...
Throughout 2024, the FDA issued new drug approvals and expanded treatment indications across various rheumatologic diseases.
REGENXBIO Inc. (Nasdaq: RGNX) today announced that AFFINITY DUCHENNE®, the multi-center, open-label trial of RGX-202, a ...
Recently, Capricor announced that it had initiated its rolling Biologics License Application (BLA) submission process with the U.S. FDA seeking full approval of deramiocel to treat all patients ...
Regenxbio’s investigational gene therapy improved muscle function for patients with Duchenne muscular dystrophy (DMD) in a phase 1/2 study. | Regenxbio’s investigational gene therapy improved muscle ...
Elevidys, a gene therapy from Sarepta Therapeutics (SRPT.O), opens new tab approved in the United States last year for ...
a potential best-in-class gene therapy for Duchenne muscular dystrophy, has advanced to pivotal stage and dosed its first patient. The company also announced new, positive efficacy and safety ...
It’s easy for those who play or watch the best movies based on video games to want to be immersed in that fictional world.
Columnist Shalom Lim tells an international conference about his experiences with inclusion during his education in Singapore ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback